Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignancies and is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• LV20.19 CAR T-cells
• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Status: RECRUITING